Asti Jackson1, Y Alkhlaif2, R L Papke3, D H Brunzell2, M I Damaj2. 1. Department of Psychiatry, Yale School of Medicine, 34 Park St., New Haven, CT, 06519, USA. asti.jackson@yale.edu. 2. Department of Pharmacology and Toxicology, School of Medicine, Virginia Commonwealth University, Richmond, VA, 23298-0613, USA. 3. Department of Pharmacology and Therapeutics, University of Florida, PO Box 100267, Gainesville, FL, 32610-0267, USA.
Abstract
RATIONALE: The α7 nicotinic acetylcholine receptor (nAChR) has been implicated as a target in modulating nicotine reward. However, the effect of pharmacological agents that have been shown to alter the channel properties of the α7 nAChR is not well understood in nicotine reward. OBJECTIVES: This study aimed to investigate the impact of α7 nAChR pharmacological modulation on nicotine conditioned place preference (CPP) in mice by using positive allosteric modulators (PAMs) and a silent agonist. METHODS: The effect of the orthosteric α7 nAChR full agonist PNU282987 (1.3 and 9 mg/kg, s.c.), Type I α7 PAM NS1738 (1 and 10 mg/kg; i.p.), the Type II α7 PAM PNU120596 (0.3, 1, and 3 mg/kg, i.p.), and the α7 silent agonist NS6740 (1 and 3 mg/kg, i.p) on nicotine CPP was measured in mice. Mice were conditioned with either saline or nicotine (0.5 mg/kg) for 3 days in the CPP paradigm. RESULTS: The α7 full orthosteric agonist PNU282987 and the Type II α7 nAChR PAM PNU120596 reduced nicotine CPP, while the silent agonist NS6740 and Type I PAM NS1738 had no effect. The effects of PNU282987 and PNU120596 did not have an effect on morphine CPP. CONCLUSIONS: Taken together, our results suggest that modulation of the α7 nAChR can play important roles in nicotine CPP in mice. In addition, the Type II α7 nAChR PAM PNU120596 attenuated nicotine reward suggesting that endogenous acetylcholine/choline tone is sufficient to reduce nicotine CPP. These findings highlight a beneficial effect of using α7 nAChR PAMs in nicotine reward.
RATIONALE: The α7 nicotinic acetylcholine receptor (nAChR) has been implicated as a target in modulating nicotine reward. However, the effect of pharmacological agents that have been shown to alter the channel properties of the α7 nAChR is not well understood in nicotine reward. OBJECTIVES: This study aimed to investigate the impact of α7 nAChR pharmacological modulation on nicotine conditioned place preference (CPP) in mice by using positive allosteric modulators (PAMs) and a silent agonist. METHODS: The effect of the orthosteric α7 nAChR full agonist PNU282987 (1.3 and 9 mg/kg, s.c.), Type I α7 PAM NS1738 (1 and 10 mg/kg; i.p.), the Type II α7 PAM PNU120596 (0.3, 1, and 3 mg/kg, i.p.), and the α7 silent agonist NS6740 (1 and 3 mg/kg, i.p) on nicotine CPP was measured in mice. Mice were conditioned with either saline or nicotine (0.5 mg/kg) for 3 days in the CPP paradigm. RESULTS: The α7 full orthosteric agonist PNU282987 and the Type II α7 nAChR PAM PNU120596 reduced nicotine CPP, while the silent agonist NS6740 and Type I PAM NS1738 had no effect. The effects of PNU282987 and PNU120596 did not have an effect on morphine CPP. CONCLUSIONS: Taken together, our results suggest that modulation of the α7 nAChR can play important roles in nicotine CPP in mice. In addition, the Type II α7 nAChR PAM PNU120596 attenuated nicotine reward suggesting that endogenous acetylcholine/choline tone is sufficient to reduce nicotine CPP. These findings highlight a beneficial effect of using α7 nAChR PAMs in nicotine reward.
Entities:
Keywords:
Conditioned place preference; Mice; Nicotine; Reward
Authors: Thomas J Hopkins; Laura E Rupprecht; Matthew R Hayes; Julie A Blendy; Heath D Schmidt Journal: Neuropsychopharmacology Date: 2012-06-06 Impact factor: 7.853
Authors: Georg Winterer; Jürgen Gallinat; Jürgen Brinkmeyer; Francesco Musso; Johannes Kornhuber; Norbert Thuerauf; Dan Rujescu; Reyna Favis; Yu Sun; Monique A Franc; Sivi Ouwerkerk-Mahadevan; Luc Janssens; Maarten Timmers; Johannes R Streffer Journal: Neuropharmacology Date: 2012-07-02 Impact factor: 5.250
Authors: Kenneth A Perkins; K N Roy Chengappa; Joshua L Karelitz; Margaret C Boldry; Valerie Michael; Taylor Herb; Jessica Gannon; Jaspreet Brar; Lisa Ford; Stefanie Rassnick; Darlene H Brunzell Journal: Neuropsychopharmacology Date: 2017-11-29 Impact factor: 7.853
Authors: Natalia M Kowal; Philip K Ahring; Vivian W Y Liao; Dinesh C Indurti; Benjamin S Harvey; Susan M O'Connor; Mary Chebib; Elin S Olafsdottir; Thomas Balle Journal: Br J Pharmacol Date: 2018-06-07 Impact factor: 8.739
Authors: Marek Samochocki; Anja Höffle; Andreas Fehrenbacher; Ruth Jostock; Jürgen Ludwig; Claudia Christner; Martin Radina; Marion Zerlin; Christoph Ullmer; Edna F R Pereira; Hermann Lübbert; Edson X Albuquerque; Alfred Maelicke Journal: J Pharmacol Exp Ther Date: 2003-03-20 Impact factor: 4.030
Authors: Phil D Livingstone; Jayaraman Srinivasan; James N C Kew; Lee A Dawson; Cecilia Gotti; Milena Moretti; Mohammed Shoaib; Susan Wonnacott Journal: Eur J Neurosci Date: 2009-01-28 Impact factor: 3.386